Tokyo Tape
Sign in
← Nipro

Half-year report · Q2

8086.TEDINET S100UQIB
Period2024-04-01 → 2024-09-30
Filed2024-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 47
MetricValuePeriodScopeSource row
Revenue¥312.0bn2024-04-01 → 2024-09-30Cons.Net sales
Revenue¥586.8bn2023-04-01 → 2024-03-31Cons.Net sales (5-year summary)
Revenue¥285.9bn2023-04-01 → 2023-09-30Cons.Net sales
Operating income¥13.5bn2024-04-01 → 2024-09-30Cons.Operating income
Operating income¥13.5bn2023-04-01 → 2023-09-30Cons.Operating income
Ordinary income¥4.5bn2024-04-01 → 2024-09-30Cons.Ordinary income
Ordinary income¥19.5bn2023-04-01 → 2024-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥14.7bn2023-04-01 → 2023-09-30Cons.Ordinary income
Profit before tax¥4.1bn2024-04-01 → 2024-09-30Cons.Income before income taxes
Profit before tax¥17.5bn2023-04-01 → 2023-09-30Cons.Income before income taxes
Net income (owners)¥129m2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥11.1bn2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥9.9bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income¥813m2024-04-01 → 2024-09-30Cons.Profit loss
Net income¥10.4bn2023-04-01 → 2023-09-30Cons.Profit loss
Total assets¥1.17Tat 2024-09-30Cons.Assets
Total assets¥1.11Tat 2024-03-31Cons.Assets
Total assets¥1.10Tat 2023-09-30Cons.Total assets (5-year summary)
Total liabilities¥875.4bnat 2024-09-30Cons.Liabilities
Total liabilities¥840.0bnat 2024-03-31Cons.Liabilities
Net assets / equity¥298.1bnat 2024-09-30Cons.Net assets
Net assets / equity¥269.8bnat 2024-03-31Cons.Net assets
Net assets / equity¥274.0bnat 2023-09-30Cons.Net assets (5-year summary)
Cash and deposits¥92.6bnat 2024-09-30Cons.Cash and deposits
Cash and deposits¥99.7bnat 2024-03-31Cons.Cash and deposits
Cash & equivalents¥85.0bnat 2024-09-30Cons.Cash and cash equivalents
Cash & equivalents¥96.6bnat 2024-03-31Cons.Cash and cash equivalents
Cash & equivalents¥83.8bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥84.7bnat 2023-03-31dCons.Cash and cash equivalents
Operating cash flow¥15.0bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥72.9bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥18.7bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥54.8bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥87.1bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥35.5bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Financing cash flow¥23.3bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities
Financing cash flow¥22.1bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥8.9bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥0.792024-04-01 → 2024-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥68.122023-04-01 → 2024-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥60.892023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥0.72024-04-01 → 2024-09-30Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥60.352023-04-01 → 2024-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥53.952023-04-01 → 2023-09-30Cons.Diluted earnings per share (5-year summary)
Equity ratio22.1%at 2024-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio21.0%at 2024-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio21.6%at 2023-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 54
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2024-04-01 → 2024-09-30¥3.0bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2024-04-01 → 2024-09-30¥383m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2024-04-01 → 2024-09-30¥2.6bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2024-04-01 → 2024-09-30−¥272m
Reconciling Itemsreconcilingrevenue2024-04-01 → 2024-09-30−¥39.9bn
Reconciling Itemsreconcilingrevenue intersegment2024-04-01 → 2024-09-30−¥39.9bn
Reconciling Itemsreconcilingsegment profit2024-04-01 → 2024-09-30−¥14.9bn
jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segmentrevenue2024-04-01 → 2024-09-30¥245.6bn
jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segmentrevenue external2024-04-01 → 2024-09-30¥242.1bn
jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥3.6bn
jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segmentsegment profit2024-04-01 → 2024-09-30¥24.5bn
jpcrp040300-q2r_E02688-000Medicine Relatedreportable segmentrevenue2024-04-01 → 2024-09-30¥68.4bn
jpcrp040300-q2r_E02688-000Medicine Relatedreportable segmentrevenue external2024-04-01 → 2024-09-30¥38.0bn
jpcrp040300-q2r_E02688-000Medicine Relatedreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥30.4bn
jpcrp040300-q2r_E02688-000Medicine Relatedreportable segmentsegment profit2024-04-01 → 2024-09-30¥3.2bn
jpcrp040300-q2r_E02688-000Pharma Packagingreportable segmentrevenue2024-04-01 → 2024-09-30¥34.9bn
jpcrp040300-q2r_E02688-000Pharma Packagingreportable segmentrevenue external2024-04-01 → 2024-09-30¥31.6bn
jpcrp040300-q2r_E02688-000Pharma Packagingreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥3.3bn
jpcrp040300-q2r_E02688-000Pharma Packagingreportable segmentsegment profit2024-04-01 → 2024-09-30¥931m
—segment totalrevenue2024-04-01 → 2024-09-30¥348.9bn
—segment totalrevenue external2024-04-01 → 2024-09-30¥311.6bn
—segment totalrevenue intersegment2024-04-01 → 2024-09-30¥37.3bn
—segment totalsegment profit2024-04-01 → 2024-09-30¥28.7bn
Total Of Reportable Segments And Otherssegment totalrevenue2024-04-01 → 2024-09-30¥351.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2024-04-01 → 2024-09-30¥312.0bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2024-04-01 → 2024-09-30¥39.9bn
Total Of Reportable Segments And Otherssegment totalsegment profit2024-04-01 → 2024-09-30¥28.4bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-04-01 → 2023-09-30¥2.5bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-04-01 → 2023-09-30¥417m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-04-01 → 2023-09-30¥2.0bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-04-01 → 2023-09-30−¥109m
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥36.1bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥36.1bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥14.1bn
jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segmentrevenue2023-04-01 → 2023-09-30¥223.6bn
jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segmentrevenue external2023-04-01 → 2023-09-30¥220.2bn
jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥3.3bn
jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segmentsegment profit2023-04-01 → 2023-09-30¥22.6bn
jpcrp040300-q2r_E02688-000Medicine Relatedreportable segmentrevenue2023-04-01 → 2023-09-30¥62.9bn
jpcrp040300-q2r_E02688-000Medicine Relatedreportable segmentrevenue external2023-04-01 → 2023-09-30¥35.2bn
jpcrp040300-q2r_E02688-000Medicine Relatedreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥27.6bn
jpcrp040300-q2r_E02688-000Medicine Relatedreportable segmentsegment profit2023-04-01 → 2023-09-30¥3.7bn
jpcrp040300-q2r_E02688-000Pharma Packagingreportable segmentrevenue2023-04-01 → 2023-09-30¥33.0bn
jpcrp040300-q2r_E02688-000Pharma Packagingreportable segmentrevenue external2023-04-01 → 2023-09-30¥30.0bn
jpcrp040300-q2r_E02688-000Pharma Packagingreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥3.1bn
jpcrp040300-q2r_E02688-000Pharma Packagingreportable segmentsegment profit2023-04-01 → 2023-09-30¥1.4bn
—segment totalrevenue2023-04-01 → 2023-09-30¥319.5bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥285.4bn
—segment totalrevenue intersegment2023-04-01 → 2023-09-30¥34.0bn
—segment totalsegment profit2023-04-01 → 2023-09-30¥27.7bn
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-09-30¥321.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-09-30¥285.9bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-09-30¥36.1bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-09-30¥27.6bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 641
ItemContextValueUnit
Other ioaCurrentQuarterInstant29208000000JPY
Allowance for doubtful accounts ioa by groupPrior1YearInstant-7139000000JPY
Allowance for doubtful accounts ioa by groupCurrentQuarterInstant-7217000000JPY
Investments and other assetsPrior1YearInstant69007000000JPY
Investments and other assetsCurrentQuarterInstant66234000000JPY
Noncurrent assetsPrior1YearInstant585655000000JPY
Noncurrent assetsCurrentQuarterInstant608901000000JPY
AssetsPrior1YearInstant1109821000000JPY
AssetsCurrentQuarterInstant1173557000000JPY
Notes and accounts payable tradePrior1YearInstant81502000000JPY
Notes and accounts payable tradeCurrentQuarterInstant83761000000JPY
Short term loans payablePrior1YearInstant160367000000JPY
Short term loans payableCurrentQuarterInstant190934000000JPY
Commercial papers liabilitiesPrior1YearInstant20000000000JPY
Commercial papers liabilitiesCurrentQuarterInstant20000000000JPY
Current portion of bondsPrior1YearInstant4700000000JPY
Current portion of bondsCurrentQuarterInstant4200000000JPY
Lease obligations clPrior1YearInstant4748000000JPY
Lease obligations clCurrentQuarterInstant5075000000JPY
Accounts payable otherPrior1YearInstant25837000000JPY
Accounts payable otherCurrentQuarterInstant24416000000JPY
Income taxes payablePrior1YearInstant6125000000JPY
Income taxes payableCurrentQuarterInstant2680000000JPY
Advances receivedPrior1YearInstant368000000JPY
Advances receivedCurrentQuarterInstant608000000JPY
Unearned revenuePrior1YearInstant345000000JPY
Unearned revenueCurrentQuarterInstant359000000JPY
Provision for bonusesPrior1YearInstant11436000000JPY
Provision for bonusesCurrentQuarterInstant9107000000JPY
Provision for directors bonusesPrior1YearInstant11000000JPY
Provision for directors bonusesCurrentQuarterInstant3000000JPY
Notes payable facilitiesPrior1YearInstant5591000000JPY
Notes payable facilitiesCurrentQuarterInstant3921000000JPY
Other clPrior1YearInstant45439000000JPY
Other clCurrentQuarterInstant51511000000JPY
Current liabilitiesPrior1YearInstant366475000000JPY
Current liabilitiesCurrentQuarterInstant396579000000JPY
Bonds payablePrior1YearInstant82000000000JPY
Bonds payableCurrentQuarterInstant81500000000JPY
Convertible bond type bonds with subscription rights to sharesPrior1YearInstant30150000000JPY
Convertible bond type bonds with subscription rights to sharesCurrentQuarterInstant30120000000JPY
Long term loans payablePrior1YearInstant302819000000JPY
Long term loans payableCurrentQuarterInstant308425000000JPY
Lease obligations nclPrior1YearInstant25312000000JPY
Lease obligations nclCurrentQuarterInstant25900000000JPY
Deferred tax liabilitiesPrior1YearInstant1619000000JPY
Deferred tax liabilitiesCurrentQuarterInstant1594000000JPY
Net defined benefit liabilityPrior1YearInstant5675000000JPY
Net defined benefit liabilityCurrentQuarterInstant5919000000JPY
Provision for directors retirement benefitsPrior1YearInstant557000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2024-03-31pass rounding
balance sheet identityconsolidated 2024-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2024-03-31pass
statement vs summary · net assetsconsolidated 2024-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2024-04-01/2024-09-30pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsconsolidated 2024-09-30pass